Specialty Pharma, Generics M&A Frenzy To Continue Into 2016: NomuraMani
The specialty pharmaceutical and generics M&A frenzy that continues to fuel strong sector performance is being driven by a host of factors which could continue to drive M&A activity into 2016, notes Nomura.
Shibani Malhotra and Austin Nelson of Nomura in their September 28, 2015 research note on “Equity: Americas Specialty Pharmaceuticals & Generics” believe sector consolidation will continue as the overall pharmaceutical industry witnesses an increasingly challenging macroeconomic environment.
M&A remains the driver of . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible